DK96588A - Antitumirmiddel indeholdende makromolekylaere platinforbindelser - Google Patents

Antitumirmiddel indeholdende makromolekylaere platinforbindelser

Info

Publication number
DK96588A
DK96588A DK096588A DK96588A DK96588A DK 96588 A DK96588 A DK 96588A DK 096588 A DK096588 A DK 096588A DK 96588 A DK96588 A DK 96588A DK 96588 A DK96588 A DK 96588A
Authority
DK
Denmark
Prior art keywords
antitumir
platino
compounds
agent containing
containing macromolecular
Prior art date
Application number
DK096588A
Other languages
English (en)
Other versions
DK96588D0 (da
Inventor
Anthony J Serino
Geoffrey W Henson
David A Schwartz
Donald H Picker
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Publication of DK96588D0 publication Critical patent/DK96588D0/da
Publication of DK96588A publication Critical patent/DK96588A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK096588A 1987-02-25 1988-02-24 Antitumirmiddel indeholdende makromolekylaere platinforbindelser DK96588A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/018,715 US4793986A (en) 1987-02-25 1987-02-25 Macromolecular platinum antitumor compounds

Publications (2)

Publication Number Publication Date
DK96588D0 DK96588D0 (da) 1988-02-24
DK96588A true DK96588A (da) 1988-08-26

Family

ID=21789419

Family Applications (1)

Application Number Title Priority Date Filing Date
DK096588A DK96588A (da) 1987-02-25 1988-02-24 Antitumirmiddel indeholdende makromolekylaere platinforbindelser

Country Status (12)

Country Link
US (1) US4793986A (da)
EP (1) EP0280474B1 (da)
JP (1) JPS63284134A (da)
AT (1) ATE96679T1 (da)
AU (1) AU596774B2 (da)
CA (1) CA1305665C (da)
DE (1) DE3885317T2 (da)
DK (1) DK96588A (da)
IE (1) IE63003B1 (da)
NO (1) NO175964C (da)
NZ (1) NZ223549A (da)
ZA (1) ZA881077B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952676A (en) * 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
US4956454A (en) * 1984-06-27 1990-09-11 Johnson Matthey Plc Monoclonal antibody - platinum co-ordination compound complex
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
SU1685944A1 (ru) * 1988-06-06 1991-10-23 Институт Физической Химии Им.Л.В.Писаржевского Способ получени комплексного соединени платины (II) с высокомолекул рной н-ДНК из селезенки крупного рогатого скота марки А, обладающего противоопухолевой активностью
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
WO1990010709A2 (en) * 1989-03-14 1990-09-20 Board Of Regents Of The University Of Nebraska Monoclonal antibodies for metallic cations on small molecules
US5972656A (en) * 1989-03-14 1999-10-26 Bionebraska, Inc. Mercury binding polypeptides and nucleotides coding therefore
DE69112684T2 (de) * 1990-04-06 1996-02-01 Univ Tulane LHRH-Analoge.
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
WO1995009868A1 (fr) * 1993-10-04 1995-04-13 Institut Pasteur Composes modifiant la transmission serotoninergique; applications diagnostiques et therapeutiques
DE69520528T2 (de) * 1994-06-14 2001-09-27 Raffinerie Tirlemontoise, S.A. Verwendung einer Zusammensetzung enthaltend Inulin oder Oligofructose als Antikrebsmittel
WO1996000079A1 (en) * 1994-06-27 1996-01-04 The General Hospital Corporation Graft co-polymer adducts of platinum (ii) compounds
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6111079A (en) * 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
ATE317703T1 (de) * 1997-06-12 2006-03-15 Innovata Plc Polymer-wirkstoff-konjugate zur behandlung von krebs
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6692734B2 (en) * 2000-01-04 2004-02-17 Access Pharmaceuticals, Inc. N,O-amidomalonate platinum complexes
AU2001247697B2 (en) 2000-03-22 2006-06-22 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US20030082102A1 (en) * 2001-06-25 2003-05-01 Court Wayne S. Radioactive platinum complexes for cancer treatment
US7838619B2 (en) 2002-01-14 2010-11-23 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
WO2004009082A1 (en) 2002-07-19 2004-01-29 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
ES2365918T3 (es) 2003-09-05 2011-10-13 The General Hospital Corporation Conjugados de poliacetal-fármaco como sistema de liberación.
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
EP1745802A1 (en) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
WO2007126078A1 (ja) * 2006-04-27 2007-11-08 Onecell Inc. ヌクレオチド-遷移金属錯体触媒
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US20080300389A1 (en) * 2007-06-04 2008-12-04 Yang David J Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
PA8853201A1 (es) 2008-12-10 2010-07-27 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
NL2020120B1 (en) * 2017-12-19 2019-06-26 Linxis B V Methods for preparing cell targeting conjugates and conjugates obtainable by said methods
NL2020121B1 (en) * 2017-12-19 2019-06-26 Linxis B V Platinum-based functional moieties for preparing cell targeting conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
IL66338A (en) * 1982-07-15 1986-03-31 Yeda Res & Dev Anti-cancer drugs comprising platinum complexed antitumor immunoglobulins
US4584392A (en) * 1982-11-10 1986-04-22 Inco Alloys International, Inc. Platinum and palladium complexes
IL67789A (en) * 1983-01-31 1986-09-30 Yissum Res Dev Co Amino-substituted malonato platinum(ii)complexes and method for their preparation
US4673754A (en) * 1983-10-14 1987-06-16 Inco Alloys International, Inc. Platinum and palladium complexes
EP0167310B1 (en) * 1984-06-27 1991-05-29 Johnson Matthey Public Limited Company Platinum co-ordination compounds
IL73972A0 (en) * 1984-12-31 1985-03-31 Yeda Res & Dev Agents based on platinum compounds

Also Published As

Publication number Publication date
DE3885317D1 (de) 1993-12-09
JPS63284134A (ja) 1988-11-21
NO175964B (no) 1994-10-03
DE3885317T2 (de) 1994-03-03
EP0280474A3 (en) 1990-01-31
CA1305665C (en) 1992-07-28
ATE96679T1 (de) 1993-11-15
EP0280474A2 (en) 1988-08-31
EP0280474B1 (en) 1993-11-03
NO880705L (no) 1988-08-26
AU1213588A (en) 1988-09-01
IE63003B1 (en) 1995-03-08
DK96588D0 (da) 1988-02-24
NO880705D0 (no) 1988-02-17
US4793986A (en) 1988-12-27
AU596774B2 (en) 1990-05-10
ZA881077B (en) 1988-08-11
IE880498L (en) 1988-08-25
NZ223549A (en) 1989-10-27
NO175964C (no) 1995-01-11

Similar Documents

Publication Publication Date Title
DK96588D0 (da) Antitumirmiddel indeholdende makromolekylaere platinforbindelser
KE3758A (en) Novel antihistamines,process for their preparation and pharmaceutical compositions containing them
FR2680507B1 (fr) Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NZ192195A (en) 1-triazolyl-2-hydroxy-2-phenyl-3-aryl-propanes and pharmaceutical compositions
DE69113221D1 (en) Antiatherosclerotische und antithrombotische 2-amino-6-phenyl-4h-pyran-4-one.
GR73691B (da)
JPS5533497A (en) Silaasubstituted 1*44dihydropyridine derivative
SE8002831L (sv) Oxitetracyklinberedningar
PT81093B (pt) Processo para a preparacao de uma composicao terapeutica para tratamento de um tumor
DK444982A (da) Substituerede hydroxymalonsyrediamider, fremgangsmaade til fremstilling deraf samt deres anvendelse som skadedyrsbekaempende midler
DK398483A (da) Substituerede tert.butanol-derivater, fremgangsmaader til fremstilling deraf samt antimykotiske midler indeholdende disse forbindelser
ES472640A1 (es) Procedimiento para preparar seudotrisacaridos
ATE3036T1 (de) 2-substituierte-4-alkyl bzw trihaloalkyl-5oxazolcarbons[urederivate, deren verwendung als antidote fuer kulturpflanzen und sie enthaltende zusammensetzungen.
DE3165050D1 (en) Salt of furosemide or piretanide as acid component and penbutolol as base component and pharmaceutical composition containing both of the said components
DE69003050D1 (de) S-substituierte beta-Thioacrylamide und deren Verwendung als Mikrobizide.
DK305184A (da) Hexahydropyrrolo(2,1-a)isoquinolin-derivater
ES8505351A1 (es) Un procedimiento para preparar nuevas aroilimidazolonas
JPS55127379A (en) Novel 33sulfonyllbenzoo1*2*44triazine and 33sulfonyllbenzoo1*2*44triazinee11oxide
EP0043976A3 (en) Anti-tumor agent
ES8103760A1 (es) Procedimiento de preparacion de (20 s) - 3 - - ((aminoace- til)amino)-5 - - pregnan- 20 - ol
IT8220082A0 (it) Composizione atta al trattamento terapeutico dei tumori.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment